Wells Fargo has initiated coverage on Natera Inc (NTRA) with an Equal-Weight rating, marking the firm's first assessment of the biotechnology company. This rating reflects their analysis of Natera's business, industry dynamics, and growth prospects.
Headquartered in Austin, Texas, Natera is a diagnostics company specializing in genetic testing services. The firm employs 4,424 full-time workers and has developed a range of innovative products, including the Panorama non-invasive prenatal test and the Signatera tumor-specific assay, aimed at personalized cancer care. With a market capitalization of $30.7 billion, Natera's financial performance has shown volatility, with a trailing twelve-month EPS of -2.28.
Upcoming earnings are slated for August 5, 2026, with an estimated EPS of -0.53 and expected revenue of $635.9 million. Recent earnings reports have shown mixed results, including a disappointing Q3 2025 EPS of -0.64, which fell short of the estimate by 68.2%.
Analyst ratings, such as Wells Fargo's, provide valuable insights based on extensive research and financial modeling. However, these assessments are based on assumptions that may not always come to fruition. As such, investors should consider a variety of factors, including company fundamentals and industry trends, when making decisions. It's also important to note that analyst ratings can evolve as new information becomes available, and differing opinions may arise among analysts covering the same company.